Joseph P. Hagan, President and CEO at Regulus Therapeutics Inc. (RGLS), sold 4,375 shares at $0.55 ($2K) on 2019-08-15, disclosed to the SEC on 2019-08-16.
Scheduled sale ($2k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RGLS | SELL | 2024-01-18 | $17K | — | Filing → |
| AUPH | SELL | 2023-05-23 | $3K | — | Filing → |
| RGLS | BUY | 2022-01-26 | $22K | — | Filing → |